Guidelines for Diagnosis and Management of Late Post‑operative Seroma after Modified Radical Mastectomy

Diagnostic Workup

Perform ultrasound‑guided aspiration of any late‑presenting seroma and send the fluid for cytologic evaluation (including cytocentrifugation with Wright‑Giemsa staining) to exclude breast‑implant‑associated anaplastic large‑cell lymphoma (BIA‑ALCL), even in patients without implants. 1
Prepare a cell‑block from the aspirated fluid for histology (H&E), immunohistochemistry (CD30‑positive, ALK‑negative) and PCR‑based T‑cell receptor gene rearrangement testing to further rule out BIA‑ALCL. 1
Clinical assessment remains essential; local recurrence after mastectomy occurs in approximately 1–2 % of patients per year and may manifest as palpable abnormalities in the skin, subcutaneous tissue, or deep to the pectoralis muscle. 2, 3, 4

Avoid excisional biopsy of seromas that have been clearly identified as benign on cytology, as it adds unnecessary morbidity. 1
Never assume a late seroma is benign without cytologic confirmation; BIA‑ALCL, although primarily linked to implant reconstruction, can present as a fluid collection and requires early diagnosis for optimal outcomes. 1
Do not rely solely on imaging; large seromas can obscure residual calcifications on mammography, making clinical correlation mandatory. 1

Fat necrosis is the most common early postoperative finding after mastectomy and may present as a palpable mass; it should be distinguished from recurrent disease. 2, 3, 4

Monitor seroma patients for signs of infection (e.g., erythema, warmth, fever, purulent drainage) and intervene promptly if these develop. 1
Assess for recurrent breast cancer, recognizing that 2–15 % of patients develop recurrence after mastectomy, with rates varying by initial tumor type and stage. 2, 3, 4

Strength of evidence: Specific levels of evidence were not provided in the cited sources.